Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

Donald Trump has threatened to introduce tariffs of up to 200pc on pharmaceutical imports in a bid to force more drugmakers ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

US President Donald Trump has threatened to impose tariffs at a rate as high as 200pc on imported drugs on Tuesday night in ...

Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its ...

Major new analysis from the Thrombotic Thrombocytopenia Syndrome (TTS) Consortium has provided critical insights into the ...

AstraZeneca PLC closed 22.77% short of its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.